Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Cyanobacteria-From the Oceans to the Potential Biotechnological and Biomedical Applications
Stockholm University, Faculty of Science, Department of Molecular Biosciences, The Wenner-Gren Institute.
Show others and affiliations
Number of Authors: 132021 (English)In: Marine Drugs, E-ISSN 1660-3397, Vol. 19, no 5, article id 241Article, review/survey (Refereed) Published
Abstract [en]

Cyanobacteria are photosynthetic prokaryotic organisms which represent a significant source of novel, bioactive, secondary metabolites, and they are also considered an abundant source of bioactive compounds/drugs, such as dolastatin, cryptophycin 1, curacin toyocamycin, phytoalexin, cyanovirin-N and phycocyanin. Some of these compounds have displayed promising results in successful Phase I, II, III and IV clinical trials. Additionally, the cyanobacterial compounds applied to medical research have demonstrated an exciting future with great potential to be developed into new medicines. Most of these compounds have exhibited strong pharmacological activities, including neurotoxicity, cytotoxicity and antiviral activity against HCMV, HSV-1, HHV-6 and HIV-1, so these metabolites could be promising candidates for COVID-19 treatment. Therefore, the effective large-scale production of natural marine products through synthesis is important for resolving the existing issues associated with chemical isolation, including small yields, and may be necessary to better investigate their biological activities. Herein, we highlight the total synthesized and stereochemical determinations of the cyanobacterial bioactive compounds. Furthermore, this review primarily focuses on the biotechnological applications of cyanobacteria, including applications as cosmetics, food supplements, and the nanobiotechnological applications of cyanobacterial bioactive compounds in potential medicinal applications for various human diseases are discussed.

Place, publisher, year, edition, pages
2021. Vol. 19, no 5, article id 241
Keywords [en]
cyanobacteria, clinical trials, antioxidant, antiviral, COVID-19, dietary supplements, biotechnological applications, total synthesis
National Category
Biological Sciences Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:su:diva-195242DOI: 10.3390/md19050241ISI: 000654546100001PubMedID: 33923369OAI: oai:DiVA.org:su-195242DiVA, id: diva2:1584347
Available from: 2021-08-11 Created: 2021-08-11 Last updated: 2024-07-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Khalifa, Shaden A. M.Saied, Essa M.Jassbi, Amir RezaRateb, Mostafa E.Du, MingXiao, JianboGuo, Zhiming

Search in DiVA

By author/editor
Khalifa, Shaden A. M.Saied, Essa M.Jassbi, Amir RezaRateb, Mostafa E.Du, MingAbdel-Daim, Mohamed M.Xiao, JianboGuo, Zhiming
By organisation
Department of Molecular Biosciences, The Wenner-Gren Institute
In the same journal
Marine Drugs
Biological SciencesPharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 39 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf